Targeting CDCA3 Enhances Sensitivity to Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer

被引：0
作者：
Adams, M. [1 ]
Burgess, J. [1 ]
Richard, D. [1 ]
O'Byrne, K. [2 ]
机构：
[1] Inst Hlth & Biomed Innovat, Translat Res Inst, Woolloongabba, Qld, Australia
[2] Inst Hlth & Biomed Innovat, Translat Res Inst, Brisbane, Qld, Australia
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
non-small cell lung cancer; prognostic factor; cisplatin chemotherapy;
D O I：
10.1016/j.jtho.2017.09.468
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA 03.11
引用
收藏
页码：S1810 / S1811
页数：2
相关论文
共 50 条
[21]   Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1 [J].
Hamilton, Gerhard ;
Rath, Barbara .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2018, 14 (01) :17-24
[22]   Chemotherapy-induced leukopenia as a prognostic factor in patients with metastatic non-small cell lung cancer treated with platinum-based chemotherapy [J].
Huang, Aimi ;
Ma, Meili ;
Jin, Bo ;
Han, Baohui .
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (02) :5241-5248
[23]   Immunonutritional Indices in Non-small-cell Lung Cancer Patients Receiving Adjuvant Platinum-based Chemotherapy [J].
Matsubara, Taichi ;
Hirai, Fumihiko ;
Yamaguchi, Masafumi ;
Hamatake, Motoharu .
ANTICANCER RESEARCH, 2021, 41 (10) :5157-5163
[24]   ERCC1 as a marker of prognosis and sensitivity to platinum-based chemotherapy in patients with stage III-IV non-small cell lung cancer [J].
Kolesnik, O. P. ;
Kuzmenko, V. O. .
PATHOLOGIA, 2020, (01) :15-20
[25]   Roles of microRNAs in the resistance to platinum based chemotherapy in the non-small cell lung cancer [J].
Zang, Hongjing ;
Peng, Jianlun ;
Wang, Weiyuan ;
Fan, Songqing .
JOURNAL OF CANCER, 2017, 8 (18) :3856-3861
[26]   Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer [J].
Wan Zhao ;
Lingmin Hu ;
Jiali Xu ;
Hongbing Shen ;
Zhibin Hu ;
Hongxia Ma ;
Yongqian Shu ;
Yongfeng Shao ;
Yongmei Yin .
Cancer Chemotherapy and Pharmacology, 2013, 71 :1287-1295
[27]   Platinum-based Doublet Chemotherapy plus Bevacizumab Without Bevacizumab Maintenance in Advanced Non-small Cell Lung Cancer (NSCLC) [J].
Noroxe, Dorte Schou ;
Wallerek, Sandra ;
Sorensen, Jens Benn .
ANTICANCER RESEARCH, 2013, 33 (08) :3275-3278
[28]   Efficacy of platinum-based chemotherapy after cranial radiation in patients with brain metastasis from non-small cell lung cancer [J].
Kim, DY ;
Lee, KW ;
Yun, T ;
Kim, DW ;
Kim, TY ;
Heo, DS ;
Bang, YJ ;
Kim, NK .
ONCOLOGY REPORTS, 2005, 14 (01) :207-211
[29]   Real-world comparison of immune checkpoint inhibitors in non-small cell lung cancer following platinum-based chemotherapy [J].
Weis, Taylor M. ;
Hough, Shannon ;
Reddy, Haritha G. ;
Daignault-Newton, Stephanie ;
Kalemkerian, Gregory P. .
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (03) :564-571
[30]   Genetic polymorphisms in XPG could predict clinical outcome of platinum-based chemotherapy for advanced non-small cell lung cancer [J].
Hu, Weicai ;
Pan, Jinbing ;
Zhao, Pu ;
Yang, Guangyu ;
Yang, Shujuan .
TUMOR BIOLOGY, 2014, 35 (06) :5561-5567
12345